A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against...

Area of Science:

• Immunology
• Vaccinology
• Molecular Biology

Background:

• The COVID-19 pandemic necessitates ongoing vaccine development against emerging SARS-CoV-2 variants.
• Existing vaccines face challenges in controlling the spread of novel variants and severe disease.
• There is a critical need for adaptable vaccine platforms to address evolving viral threats.

Purpose of the Study:

• To develop and evaluate a novel messenger RNA (mRNA) vaccine platform for SARS-CoV-2.
• To assess the immunogenicity and protective efficacy of an mRNA vaccine encoding a nanoparticle displaying multiple SARS-CoV-2 receptor binding domains (RBDs).
• To determine the vaccine's effectiveness against a specific variant of concern, the Delta variant.

Main Methods:

• Engineered an mRNA vaccine construct encoding a nanoparticle displaying 60 copies of the SARS-CoV-2 RBD.
• Utilized a construct specifically encoding the RBD from the Delta variant.
• Evaluated the vaccine's immunogenicity by measuring neutralizing antibody responses.
• Assessed protective immunity in a transgenic mouse model challenged with the Delta variant.

Main Results:

• The mRNA RBD nanoparticle vaccine demonstrated high antigenicity.
• The vaccine elicited a robust neutralizing antibody response.
• Significant protective immunity against the Delta variant was observed in the mouse model.
• The platform proved flexible for rapid vaccine development.

Conclusions:

• The developed mRNA RBD nanoparticle vaccine is a highly effective antigen delivery system.
• This vaccine platform offers a promising strategy for combating current and future SARS-CoV-2 variants.
• The adaptability of this platform suggests its potential value in addressing emerging infectious diseases.